2012
DOI: 10.1093/bioinformatics/bts156
|View full text |Cite
|
Sign up to set email alerts
|

Metab2MeSH: annotating compounds with medical subject headings

Abstract: Progress in high-throughput genomic technologies has led to the development of a variety of resources that link genes to functional information contained in the biomedical literature. However, tools attempting to link small molecules to normal and diseased physiology and published data relevant to biologists and clinical investigators, are still lacking. With metabolomics rapidly emerging as a new omics field, the task of annotating small molecule metabolites becomes highly relevant. Our tool Metab2MeSH uses a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
34
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
8
1
1

Relationship

1
9

Authors

Journals

citations
Cited by 35 publications
(34 citation statements)
references
References 14 publications
0
34
0
Order By: Relevance
“…To generate a Cytoscape network model of the lipid subclasses identified in our lipidomics experiment, we input a curated list of gene or compound identifiers from KEGG (Supplementary Data 5) into the MetScape 3 Cytoscape app as previously described 115,116 . To determine whether any of the network nodes had been associated in the literature with disorders that were phenotypically similar to ZIKV syndrome, we used the MetDisease Cytoscape app 117 to query the Metab2MeSH database 118 for seven Medical Subject Heading (MeSH) terms (‘macular degeneration’, ‘optic nerve diseases’, ‘pregnancy complications’, ‘virus diseases’, ‘brain diseases’, ‘congenital abnormalities’, ‘testicular disease’) arbitrarily selected for this purpose.…”
Section: Methodsmentioning
confidence: 99%
“…To generate a Cytoscape network model of the lipid subclasses identified in our lipidomics experiment, we input a curated list of gene or compound identifiers from KEGG (Supplementary Data 5) into the MetScape 3 Cytoscape app as previously described 115,116 . To determine whether any of the network nodes had been associated in the literature with disorders that were phenotypically similar to ZIKV syndrome, we used the MetDisease Cytoscape app 117 to query the Metab2MeSH database 118 for seven Medical Subject Heading (MeSH) terms (‘macular degeneration’, ‘optic nerve diseases’, ‘pregnancy complications’, ‘virus diseases’, ‘brain diseases’, ‘congenital abnormalities’, ‘testicular disease’) arbitrarily selected for this purpose.…”
Section: Methodsmentioning
confidence: 99%
“…Disease proteins were obtained from the Online Mendelian Inheritance in Man (OMIM) database and GWAS studies, and drug targets were obtained from DrugBank. The drug indications were obtained from the Medication Indication – High Precision Subset (MEDI-HPS) [ 23 ], which was further filtered for strong literature evidence by using the Metab2MeSH tool [ 24 ]. Finally, Guney et al manually checked all drug labels to confirm that they were used to treat the disease.…”
Section: Methodsmentioning
confidence: 99%
“…A limitation of pathway mapping is the relatively low number of metabolites included in the analysis, basically due to the lack of reliable metabolite identifiers. Generation of automated annotations [58] and construction and visualization of metabolite networks [59] attempt to overcome these challenges. Based on the observation that metabolites that are functionally related also change in a similar manner over time or over the course of an event that affects this function, data-driven analysis is another effort to include detected but still unidentified metabolites into pathway analysis [60].…”
Section: Data Analysis and Biological Interpretationmentioning
confidence: 99%